Recursion Pharmaceuticals (RXRX) Liabilities and Shareholders Equity (2020 - 2026)

Recursion Pharmaceuticals' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 2.63% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 billion (up 29.59% YoY) and the FY2025 annual result came in at $1.5 billion, up 1.76% from the prior year.
• Liabilities and Shareholders Equity was $1.3 billion for Q1 2026 at Recursion Pharmaceuticals, down from $1.5 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q4 2025 and bottomed at $557.8 million in Q1 2024.
• A 5-year average of $919.3 million and a median of $726.5 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 170.03% — and 2023, when it fell 14.56%.
• Recursion Pharmaceuticals' Liabilities and Shareholders Equity stood at $701.3 million in 2022, then fell by 6.79% to $653.7 million in 2023, then jumped by 121.6% to $1.4 billion in 2024, then grew by 1.76% to $1.5 billion in 2025, then dropped by 9.13% to $1.3 billion in 2026.
• Business Quant data shows RXRX's Liabilities and Shareholders Equity at $1.3 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.